Physical Activity Level Moderates Cannabis-Associated Reductions in Negative Affect in Anxious Individuals.

Clin TherMar 20, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Jonathon K Lisano, Luiza Rosa, Greg Giordano et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized trial’s secondary analyses examined whether physical activity modified changes in negative affect among 178 people with mild or greater anxiety who intended to use cannabis for symptom relief. Participants were assigned to use CBD-dominant, THC-dominant, or THC+CBD cannabis ad libitum for 4 weeks. Negative affect decreased over time across all groups (z = -3.47; P < 0.001), but the association varied by physical activity and product type. Higher moderate-to-vigorous physical activity was associated with a less steep decrease in negative affect among THC-dominant product users; this moderation was not observed in the other groups.

Key findings

  • Negative affect decreased over time across the cannabis groups (z = -3.47; P < 0.001).
  • For THC-dominant product users, higher versus lower MVPA was associated with a less steep decrease in negative affect (difference = -12.00; SE = 5.12; P = 0.02).
  • MVPA did not significantly moderate changes in negative affect for CBD-dominant (P = 0.76) or THC+CBD products (P = 0.28).
  • The group-by-time-by-physical-activity interaction was significant (z = 2.55; P = 0.01).

Why it matters

The findings suggest that the relationship between cannabis use and changes in negative affect may differ according to both product cannabinoid composition and physical activity. This context is relevant when interpreting symptom changes during cannabis use, but the results do not establish that cannabis or physical activity caused those changes.

What to keep in mind

These were secondary analyses, and participants used their assigned products ad libitum. Physical activity was measured only during the final 2 weeks, limiting conclusions about its relationship with changes across the full study period.

Source

Published in Clin Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.